Click here for an archive of Cramer's "Mad Money" recaps.

Genzyme's Mosaic

Genzyme ( GENZ) is a beautiful mosaic of a biotech stock and is right for this market, said Jim Cramer Tuesday on his "Mad Money" TV show.

Unlike Genentech ( DNA), which focuses on cancer drugs, Genzyme is diversified with drugs to treat all kinds of diseases, said Cramer.

Genzyme's approach is to go after niche markets with little competition where the company can dominate, said Cramer. That approach appears to be working, given the strong third-quarter results Genzyme reported Tuesday.

Cramer still likes Genentech and Amgen ( AMGN), but Genzyme should be added to the mix, he said.

In response to questions about more speculative biotech plays, Cramer said to stay away -- especially in a market like this -- unless one is just speculating with mad money.

The Accenture Nobody Knows

Following up on a question asked earlier in the show, Cramer said one absolutely should not buy ThermoGenesis ( KOOL). The company hasn't made any money in six years and its revenues "aren't happening," he said.

Cramer is bullish on Accenture ( ACN) after IBM ( IBM) reported surprisingly good results in its outsourcing and consulting business, he said.

"If IBM's consulting business can do that well ... then Accenture can doubtless do a whole lot better in this market," said Cramer.

Accenture has done a number of things to try to catch the market's attention, he said, including a Dutch tender offer, buying back stock, offering a dividend and beating earnings estimates. "But nobody cares," said Cramer.

Until last week, even Cramer would have recommended Infosys Technologies ( INFY) as the outsourcing play.

But after taking another look at Accenture, Cramer realized that Accenture has Infosys beat, and he believes investors can make a lot more money investing in Accenture, which has a cheaper stock.

At 16 times earnings, Accenture is almost a value play, he said. Cramer likes Accenture as a long-term investment because Accenture is well positioned to be the biggest beneficiary from the huge secular growth in outsourcing.

Amylin Entertainment

Senior MarketWatch columnist Herb Greenberg joined Cramer on the show. Cramer asked Greenberg about Take-Two Interactive ( TTWO), a video-game stock Greenberg has long been bearish on.

With Take-Two's stock down about 40% from its all-time high, Cramer asked Greenberg, "Don't you think at this level, the mutual funds come in and buy it?"

"Yeah, they'll buy it because they want to make the trade," said Greenberg, but, it's not about the trade, he added.

"This is a company that I see as a one-trick pony, even thought they have a lot of other games. These mutual funds think lightning is going to strike twice with this company."

Estimates are coming down, and even the bulls are throwing in the towel on this company, he said.

Cramer then asked Greenberg why he is so bullish on Amylin Pharmaceuticals ( AMLN). Greenberg said one of his best sources has been accumulating Amylin from the $14 range to the low $30s and isn't about to sell even though the stock has more than doubled from its 52-week low.

Cramer said he believes that Greenberg is right to be bearish on Take-Two, but in this tough market, Cramer can't resist taking the profits in Amylin, he said, even though long term there may be big money to be made.

Mad Mail

A viewer asked, if Google ( GOOG) reaches Cramer's $350 price target, should one sell the stock or let it ride? Cramer said he does not believe in letting one's investments ride. He would take profits "until you are finally playing with the house's money."

In response to a question about Dell ( DELL), Intel ( INTC) and Texas Instruments ( TXN), Cramer said his sources at Dell are being cautious.

Intel reported earnings Tuesday after the close which were "not what we wanted" with a "higher inventory number." The stock is "clearly not going anywhere." Texas Instruments is the one to buy, said Cramer.

Commenting on the lack of availability of Apple's ( AAPL) new video iPod, Cramer said the trade in Apple will work until Apple's new video iPod is available in abundance. After that, it will be time to ring the register.

Of TiVo's ( TIVO) partnership with Comcast ( CMCSA), Cramer said "no can do." TiVo's stock should be sold, he said.

A viewer wanted to know if Microsoft ( MSFT) is still a good play for Cramer's fourth-quarter tech rally.

Cramer said he does not believe that Microsoft's third-quarter earnings, to be announced at the end of October, will disappoint. Cramer also likes the fact that Rich Pzena, manager of the John Hancock Classic Value fund is buying Microsoft.

"It's the cheapest I've ever seen it," said Cramer. "Two thumbs up. Way up!"

Lightning Round


Cramer was bullish on Penn National Gaming ( PENN), Southwestern Energy ( SWN), Cendant ( CD), Google ( GOOG), Bristol-Myers Squibb ( BMY), American Electric Power ( AEP), PNM Resources ( PNM), Duke Energy ( DUK), J.P. Morgan Chase ( JPM), Wal-Mart Stores ( WMT), General Maritime ( GMR), Goldman Sachs ( GS) and Altria ( MO).


Cramer was bearish on Halliburton ( HAL), Sprint Nextel ( S), Valero Energy ( VLO), General Motors ( GM), BioCryst Pharmaceuticals ( BCRX), Panacos Pharmaceuticals ( PANC), Progressive ( PGR), Knightsbridge Tankers ( VLCCF), Dobson Communications ( DCEL), International Securities Exchange ( ISE), Bancolombia ( CIB) and Revlon ( REV).

1. Pigs Get Slaughtered 2. It's OK to Pay the Taxes
3. Don't Buy All at Once 4. Buy Damaged Stocks
5. Diversify to Control Risk 6. Do Your Homework
7. Don't Panic 8. Buy Best-of-Breed
9. Defend Some Stocks 10. Don't Bet on Bad Stocks
11. Own Fewer Names 12. Cash Is for Winners
13. No Regrets 14. Expect Corrections
15. Know Bonds 16. Don't Subsidize Losers
17. No Room for Hope 18. Be Flexible
19. Quit When Execs Do 20. Patience Is a Virtue
21. Be a TV Critic 22. When to Wait 30 Days
23. Beware the Hype 24. Explain Your Picks
25. Find the Bull Market
At the time of publication, Cramer was long Cendant, Microsoft, Intel, Halliburton and Altria.

James J. Cramer is a director and co-founder of He contributes daily market commentary for's sites and serves as an adviser to the company's CEO. Outside contributing columnists for and, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for ActionAlertsPLUS. While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by clicking here. Listen to Cramer's RealMoney Radio show on your computer; just click here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click here to get his second book, "You Got Screwed!" and click here to order Cramer's autobiography, "Confessions of a Street Addict."

If you liked this article you might like

Qualcomm Nets Wireless Licenses in India

Qualcomm Nets Wireless Licenses in India

SEC Probes Other Deals: Report

SEC Probes Other Deals: Report

Cramer's 'Mad Money' Follow-Up: April 15

Cramer's 'Mad Money' Follow-Up: April 15

Cramer's 'Mad Money' Follow-Up: April 14

Cramer's 'Mad Money' Follow-Up: April 14

Cramer's 'Mad Money' Follow-Up: March 25

Cramer's 'Mad Money' Follow-Up: March 25